Advaxis Profit Margin 2007-2021 | ADXS
Current and historical gross margin, operating margin and net profit margin for Advaxis (ADXS) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Advaxis net profit margin as of July 31, 2021 is 0%.
|Advaxis Annual Profit Margins
|Advaxis Quarterly Profit Margins
||Medical - Biomedical and Genetics
Advaxis, Inc. is a development stage biotechnology company focused on developing safe and effective cancer vaccines that utilize multiple mechanisms of immunity. The Company is developing a live Listeria vaccine technology under license from the University of Pennsylvania which secretes a protein sequence containing a tumor-specific antigen. The Company believes this vaccine technology is capable of stimulating the body's immune system to process and recognize the antigen as if it were foreign, generating an immune response able to attack the cancer. It also considers this to be a broadly enabling platform technology that can be applied to the treatment of many types of cancers, infectious diseases and auto-immune disorders. The Company's products in development include Lovaxin C and Lovaxin B, Lovaxin P.